Strongbridge Biopharma plc, (NASDAQ: SBBP) today announced top-line results from the multinational, pivotal Phase 3 SONICS study evaluating RECORLEV™ (levoketoconazole) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Strongbridge Biopharma (SBBP) 10% Owner Buys ~361K SharesAugust 9, 2018 12:36 PM Strongbridge Biopharma (SBBP) PT Raised to $17 at Cantor FitzgeraldAugust 8, 2018 9:24 AM Strongbridge Biopharma (SBBP) climbs 42% after announcing results from Phase 3 study evaluating RECORLEV for treatment of endogenous Cushing’s syndromeAugust 8, 2018 6:45 AM Strongbridge Biopharma plc Announces Positive Top-Line Results from the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s SyndromeAugust 8, 2018 6:30 AM